替加环素结合头孢哌酮钠舒巴坦钠治疗多药耐药鲍氏不动杆菌肺部感染患者的临床疗效

发布时间：2018-06-02 19:24

本文选题：替加环素 + 头孢哌酮钠舒巴坦钠　；参考：《中华医院感染学杂志》2017年15期

【摘要】：目的观察替加环素结合头孢哌酮钠舒巴坦钠治疗多药耐药鲍氏不动杆菌(MDR-AB)肺部感染患者的临床疗效,为临床治疗提供参考依据。方法选取2014年1月-2016年6月医院治疗的82例脑出血患者,根据随机数表法将患者分为治疗组及对照组,各41例,治疗组选用替加环素结合头孢哌酮钠舒巴坦钠进行药物治疗,对照组选用头孢哌酮钠舒巴坦钠进行药物治疗,治疗时间为2周,比较两组患者临床疗效及不良反应率。结果治疗组总有效率为73.2%,显著高于对照的48.8%,差异有统计学意义(P0.05);治疗组不良反应发生率为4.9%,对照组为9.8%,差异无统计学意义。结论在治疗MDR-AB肺炎时,替加环素联用头孢哌酮钠舒巴坦钠临床治疗有效率高,是一种理想的应用于MDR-AB肺炎的治疗方案。
[Abstract]:Objective to observe the clinical effect of tigicycline combined with cefoperazone sodium sulbactam sodium in the treatment of multidrug resistant Acinetobacter baumannii MDR-ABB patients with pulmonary infection. Methods from January 2014 to June 2016, 82 patients with intracerebral hemorrhage were randomly divided into treatment group (n = 41) and control group (n = 41). The treatment group was treated with tegicycline and cefoperazone sodium sulbactam sodium. The control group was treated with cefoperazone sodium sulbactam sodium for 2 weeks. Results the total effective rate of the treatment group was 73.2%, which was significantly higher than that of the control group (48.8%), the difference was statistically significant (P 0.05), and the incidence of adverse reactions was 4.9 in the treatment group and 9.8 in the control group, with no statistical significance. Conclusion in the treatment of MDR-AB pneumonia, tigicycline combined with cefoperazone sodium sulbactam sodium has a high effective rate and is an ideal treatment for MDR-AB pneumonia.
【作者单位】：东营市第二人民医院药械科;东营市第二人民医院质控科;东营市第二人民医院神经内科;东营市第二人民医院ICU;东营市第二人民医院呼吸内科;
【分类号】：R563.1

【参考文献】